Mid-term follow-up results of neoadjuvant sintilimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma
Haibo Cai, Liji Chen, Junjun Huang, Hongmei Ma, Shifa Zhang, Kaize Zhong, Dongbao Yang, Jiuhe Sun, Hongfeng Liu, Ru Song · 2024
Read Mid-term follow-up results of neoadjuvant sintilimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma by Haibo Cai, Liji Chen, Junjun Huang, Hongmei Ma, Shifa Zhang, Kaize Zhong, Dongbao Yang, Jiuhe Sun, Hongfeng Liu, Ru Song (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11652524.txt.
Description
Immunotherapy before surgery may extend survival in esophageal cancer, Haibo Cai and co-authors report in a 2024 follow-up study. The question was whether adding a checkpoint inhibitor to chemotherapy before surgery brings real-world survival benefits in locally advanced, resectable squamous cell cancer of the esophagus. Such combinations are moving fast in trials, but routine-practice evidence with mid-term follow-up is thinner.
Patients who had surgery at one hospital over two years were analyzed retrospectively. They split into a combined-treatment group and a surgery-only group by their treatment history. Two-year overall and disease-free survival were the primary endpoints. Safety and efficacy of the pre-surgery regimen were secondary. Readers get practice-based numbers to set beside trial results, from a cancer where recurrence after surgery is common.
Catalog record
| CREATOR | Haibo Cai, Liji Chen, Junjun Huang, Hongmei Ma, Shifa Zhang, Kaize Zhong, Dongbao Yang, Jiuhe Sun, Hongfeng Liu, Ru Song |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |